

Personal informations

Name Agostino
Surname CHIARAVALLOTI

Date of birth 24/10/1982

Education

Date of Fulfilment 26/04/2017
Title awarded PhD
Description APPLIED BIOTECHNOLOGY AND TRANSLATIONAL MEDICINE STUDY AREA
ADVANCED TECHNOLOGY IN BIOMEDICINE

Thesis Title Prognostic value of PET/CT with 18F Fluorodopamine in primary brain neoplasms

Vote earned
Name and address of institution Università di Roma Tor Vergata

Date of Fulfilment 23/07/2015
Title awarded Postgraduate school diploma
Università di Roma Tor Vergata

Vote earned 50/50 e lode
Thesis Title PET/CT with 18F FDG and 18F Florbetapir in patients with cognitive decline: relationships among imaging and biomarkers T-Tau, P-Tau and amyloid in CSF

Name and address of institution Università di Roma Tor Vergata

Date of Fulfilment 23/07/2018
Title awarded Medical Doctor
Description Degree
Vote earned 110 cum laude
Thesis Title Striatal and extrastriatal evaluation of the presynaptic dopamine transporter (DAT SCAN). Preliminary results of possible meanings in Parkinsonisms.

Name and address of institution Università degli Studi di ROMA "La Sapienza" - P.zza Aldo Moro, 5 - ROMA

Work experience

Period	19/03/2018 - present
Position	Professor
Description	Board member, doctorate APPLIED BIOTECHNOLOGY AND TRANSLATIONAL MEDICINE STUDY AREA ADVANCED TECHNOLOGY IN BIOMEDICINE
Name and address of institution	Università di Roma Tor Vergata, Dip. L.240/2010 Biomedicina e Prevenzione
Period	05/05/2017 – present
Position	Professor
Description	Professor of Nuclear Medicine (Med/36)
Name and address of institution	Faculty of Medicine and Surgery, Università Cattolica "Nostra signora del Buon Consiglio" di Tirana
Name and address of institution	Università Nostra Signora del Buon Consiglio - Tirana
Period	16/02/2017 – present
Position	Physician, ex art. 5 D. Lgs 517/99
Description	Medical care
Name and address of institution	UOC Medicina Nucleare, Policlinico Tor Vergata, Roma
Name and address of institution	POLICLINICO UNIVERSITARIO TOR VERGATA - - Roma
Period	01/09/2016 – present
Position	Professor
Description	Professor of Nuclear Medicine (Med/36)
Name and address of institution	International Medical School IMS, University Tor Vergata Università di Roma Tor Vergata, Dip. L.240/2010 Biomedicina e Prevenzione
Period	15/12/2016 – present
Position	Researcher
Description	Researcher, full time (art. 24 c.3-a L. 240/10)
Name and address of institution	Università di Roma Tor Vergata, Dip. L.240/2010 Biomedicina e Prevenzione

Period	30/06/2009 - 29/06/2014
Position	Specialist in training
Description	Specialist in training, Nuclear Medicine
Name and address of institution	Università di Roma Tor Vergata, Dip. L.240/2010 Biomedicina e Prevenzione

Scientific Responsibilities

Period	2017-2018
Position	Editor
Description	Editor, Special issue on radiopharmaceuticals
Name and address of institution	Journal: current medicinal chemistry. IF 3.45

Period	12/2016- present
Position	Researcher
Description	Lead responsible, Horizon 2020
Name and address of institution	Lead responsible, UNITOV partner, grant n°689209

Publication list (most relevant papers)

1. **Chiaravalloti A**, Castellano AE, Ricci M4, Barbagallo G, Sannino P, Ursini F, Karalis G, Schillaci O. Coupled Imaging with [18F]FBB and [18F]FDG in AD Subjects Show a Selective Association Between Amyloid Burden and Cortical Dysfunction in the Brain. *Mol Imaging Biol.* 2018 Aug;20(4):659-666. doi: 10.1007/s11307-018-1167-1.
2. **Chiaravalloti A**, Barbagallo G, Ricci M, Sannino P, Karalis G, Ursini F, Schillaci O. Ageing effect on 18F-DOPA and 123I-MIBG uptake: a cross-sectional study. *Nucl Med Commun.* 2018 Jun;39(6):539-544. doi: 10.1097/MNM.0000000000000835.
3. **Chiaravalloti A**, Di Biagio D, Tavolozza M, Calabria F, Schillaci O. PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤ 2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection? *Eur J Nucl Med Mol Imaging.* 2016 Jul;43(8):1418-24. doi: 10.1007/s00259-015-3306-0. Epub 2016 Jan 21. PubMed PMID: 26791373.
4. Liguori C, **Chiaravalloti A**, Sancesario G, Stefani A, Sancesario GM, Mercuri NB, Schillaci O, Pierantozzi M. Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimer's disease. *Eur J Nucl Med Mol Imaging.* 2016 May 25. [Epub ahead of print] PubMed PMID: 27221635.
5. Alessandrini M, Micarelli A, **Chiaravalloti A**, Bruno E, Danieli R, Pierantozzi M, Genovesi G, Öberg J, Pagani M, Schillaci O. Involvement of Subcortical Brain Structures During Olfactory Stimulation in Multiple Chemical Sensitivity (2016) *Brain Topography*, 29 (2), pp. 243-252.
5. Di Biagio D, **Chiaravalloti A**, Tavolozza M, Abbatiello P, Schillaci O. Detection of local recurrence of prostate cancer after radical prostatectomy: Is there a role for early ¹⁸F-FCH PET/CT? *Ann Nucl Med.* 2015 Dec;29(10):861-9. doi: 10.1007/s12149-015-1015-1. Epub 2015 Aug 11. PubMed PMID: 26261000.
6. Rocchi C, Pierantozzi M, Galati S, **Chiaravalloti A**, Pisani V, Prosperetti C, Lauretti B, Stampanoni Bassi M, Olivola E, Schillaci O, Stefani A. Autonomic Function Tests and MIBG in Parkinson's Disease: Correlation to Disease Duration and Motor Symptoms. *CNS Neurosci Ther.* 2015 Sep;21(9):727-32. doi: 10.1111/cns.12437. Epub 2015 Jul 24. PubMed PMID: 26205884.
7. Villani V, Carapella CM, **Chiaravalloti A**, Terrenato I, Piludu F, Vidiri A, Schillaci O, Floris R, Marzi S, Fabi A, Pace A. The Role of PET [18F]FDOPA in Evaluating Low-grade Glioma. *Anticancer Res.* 2015 Sep;35(9):5117-22. PubMed PMID: 26254416.

8. **Chiaravalloti A**, Martorana A, Koch G, Toniolo S, di Biagio D, di Pietro B, Schillaci O. Functional correlates of t-Tau, p-Tau and A β_{1-42} amyloid cerebrospinal fluid levels in Alzheimer's disease: a ^{18}F -FDG PET/CT study. *Nucl Med Commun*. 2015 May;36(5):461-8. doi: 10.1097/MNM.0000000000000272. PubMed PMID: 25646706.
9. **Chiaravalloti A**, Fiorentini A, Villani V, Carapella C, Pace A, Di Pietro B, Di Russo C, Palumbo B, Floris R, Schillaci O. Factors affecting ^{18}F FDOPA standardized uptake value in patients with primary brain tumors after treatment. *Nucl Med Biol*. 2015 Apr;42(4):355-9. doi: 10.1016/j.nucmedbio.2015.01.002. Epub 2015 Jan 9. PubMed PMID: 25624151.
10. **Chiaravalloti A**, Pagani M, Cantonetti M, Di Pietro B, Tavolozza M, Travascio L, Di Biagio D, Danieli R, Schillaci O. Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An ^{18}F -FDG PET/CT study. *Oncol Lett*. 2015 Feb;9(2):685-690. Epub 2014 Dec 3. PubMed PMID: 25621038; PubMed Central PMCID: PMC4301514.
11. **Chiaravalloti A**, Stefani A, Fiorentini A, Lacanfora A, Stanzione P, Schillaci O. Do CSF levels of t-Tau, p-Tau and β_{1-42} amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A ^{123}I -FP-CIT study in the early stages of the disease. *Eur J Nucl Med Mol Imaging*. 2014 Nov;41(11):2137-43. doi: 10.1007/s00259-014-2841-4. Epub 2014 Jul 10. Erratum in: *Eur J Nucl Med Mol Imaging*. 2014 Nov;41(11):2165-6. PubMed PMID: 25007849.
12. **Chiaravalloti A**, Stefani A, Di Biagio D, Pierantozzi M, Tavolozza M, Di Pietro B, Stanzione P, Schillaci O. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson's disease. *Ann Nucl Med*. 2013 Jun;27(5):444-51. doi: 10.1007/s12149-013-0702-z. Epub 2013 Feb 27. PubMed PMID: 23443954.
13. **Chiaravalloti A**, Stefani A, Tavolozza M, Pierantozzi M, Di Biagio D, Olivola E, Di Pietro B, Stampanoni M, Danieli R, Simonetti G, Stanzione P, Schillaci O. Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with ^{123}I -MIBG. *Mol Med Rep*. 2012 Dec;6(6):1337-42. doi: 10.3892/mmr.2012.1104. Epub 2012 Sep 27. PubMed PMID: 23023866.
14. **Schillaci O**, Chiaravalloti A, Pierantozzi M, Di Pietro B, Koch G, Bruni C, Stanzione P, Stefani A. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with ^{123}I -FP-CIT SPECT. *Int J Mol Med*. 2011 Nov;28(5):881-6. doi:

- 10.3892/ijmm.2011.764. Epub 2011 Aug 2. PubMed PMID: 21811760.
15. **Chiaravalloti A**, Danieli R, Caracciolo CR, Travascio L, Cantonetti M, Gallamini A, Guazzaroni M, Orlacchio A, Simonetti G, Schillaci O. Initial staging of Hodgkin's disease: role of contrast-enhanced 18F FDG PET/CT. *Medicine (Baltimore)*. 2014 Aug;93(8):e50. doi: 10.1097/MD.0000000000000050. PubMed PMID: 25121354; PubMed Central PMCID: PMC4602442.
16. **Chiaravalloti A**, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, Guazzaroni M, Orlacchio A, Simonetti G, Schillaci O. Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma. *Eur J Nucl Med Mol Imaging*. 2014 Jun;41(6):1123-32. doi: 10.1007/s00259-014-2703-0. Epub 2014 Feb 22. PubMed PMID: 24562647.
17. **Chiaravalloti A**, Pagani M, Micarelli A, Di Pietro B, Genovesi G, Alessandrini M, Schillaci O. Cortical activity during olfactory stimulation in multiple chemical sensitivity: a 18F-FDG PET/CT study(2015) *Eur J of Nuclear Med Mol Im*, 42 (5).
18. Micarelli A, Pagani M, **Chiaravalloti A**, Bruno E, Pavone I, Candidi M, Danieli R, Schillaci O, Alessandrini M. Cortical metabolic arrangement during olfactory processing: proposal for a 18F FDG PET/CT methodological approach. *Medicine (Baltimore)*. 2014 Oct;93(19):e103. doi: 10.1097/MD.0000000000000103. PubMed PMID: 25340494; PubMed Central PMCID: PMC4616321.
19. **Chiaravalloti A**, Pagani M, Micarelli A, Di Pietro B, Genovesi G, Alessandrini M, Schillaci O. Cortical activity during olfactory stimulation in multiple chemical sensitivity: a (18)F-FDG PET/CT study. *Eur J Nucl Med Mol Imaging*. 2015 Apr;42(5):733-40. doi: 10.1007/s00259-014-2969-2. Epub 2015 Feb 18. PubMed PMID: 25690545. **IF: 5.383**
20. **Chiaravalloti A**, Pagani M, Di Pietro B, Danieli R, Tavolozza M, Travascio L, Caracciolo CR, Simonetti G, Cantonetti M, Schillaci O. Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin's lymphoma? 2013 *Nucl Med Comm*, 34 (1), pp. 57-63.
21. Calabria F, **Chiaravalloti A**, Schillaci O. (18)F-choline PET/CT pitfalls in image interpretation: an update on 300 examined patients with prostate cancer. *Clin Nucl Med*. 2014 Feb;39(2):122-30. doi: 10.1097/RLU.0000000000000303. PubMed PMID: 24368525.